These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1521204)

  • 41. Mechanisms and avoidance of graft-versus-host disease.
    van Bekkum DW; Wagemaker G; Vriesendorp HM
    Transplant Proc; 1979 Mar; 11(1):189-95. PubMed ID: 377629
    [No Abstract]   [Full Text] [Related]  

  • 42. Thalidomide--the need for a new clinical evaluation of an old drug.
    Ehninger G; Eger K; Stuhler A; Schuler U
    Bone Marrow Transplant; 1993; 12 Suppl 3():S26-8. PubMed ID: 8124253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
    Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
    [No Abstract]   [Full Text] [Related]  

  • 44. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
    Basić-Jukić N; Labar B
    Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
    de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
    Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
    [No Abstract]   [Full Text] [Related]  

  • 46. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
    Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
    Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
    [No Abstract]   [Full Text] [Related]  

  • 48. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis.
    Donnenberg AD; Hess AD; Duff SC; Bright EC; Noga SJ; Rowley SD; Saral R; Santos GW
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):144-52. PubMed ID: 3321641
    [No Abstract]   [Full Text] [Related]  

  • 49. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract]   [Full Text] [Related]  

  • 50. New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
    Slavin S; Or R; Naparstek E; Cividalli G; Weshler Z; Weiss L; Mumcuoglu M; Engelhard D; Aker M; Pollack A
    Isr J Med Sci; 1986; 22(3-4):264-7. PubMed ID: 3528046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Thalidomide and graft verses host disease: basis for a new indication and side effects].
    López Gil JA
    Med Clin (Barc); 1992 Oct; 99(14):545-8. PubMed ID: 1434991
    [No Abstract]   [Full Text] [Related]  

  • 52. Thalidomide for severe acute graft-versus-host disease.
    Ringdén O; Aschan J; Westerberg L
    Lancet; 1988 Sep; 2(8610):568. PubMed ID: 2900947
    [No Abstract]   [Full Text] [Related]  

  • 53. [Prevention and treatment of graft-versus-host disease].
    Wiktor-Jedrzejczak W
    Acta Haematol Pol; 1987; 18(3-4):220-4. PubMed ID: 3330400
    [No Abstract]   [Full Text] [Related]  

  • 54. Improved survival in marrow recipients above 30 years of age with better prevention of graft-versus-host disease.
    Aschan J; Ringdén O; Tollemar J; Ljungman P; Lönnqvist B; Pihlstedt P; Markling L; Sundberg B
    Transplant Proc; 1990 Feb; 22(1):195-7. PubMed ID: 2309313
    [No Abstract]   [Full Text] [Related]  

  • 55. Thalidomide for graft-versus-host disease.
    McCarthy DM; Kanfer E; Taylor J; Barrett AJ
    Lancet; 1988 Nov; 2(8620):1135. PubMed ID: 2903342
    [No Abstract]   [Full Text] [Related]  

  • 56. Thalidomide for graft-versus-host disease.
    Vogelsang GB; Santos GW; Colvin OM; Chen T
    Lancet; 1988 Apr; 1(8589):827. PubMed ID: 2895345
    [No Abstract]   [Full Text] [Related]  

  • 57. Thalidomide for chronic graft-versus-host disease in children.
    Heney D; Lewis IJ; Bailey CC
    Lancet; 1988 Dec; 2(8623):1317. PubMed ID: 2904042
    [No Abstract]   [Full Text] [Related]  

  • 58. Graft-versus-host disease.
    Kaitin KI
    N Engl J Med; 1991 Aug; 325(5):357-8. PubMed ID: 2057040
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial: Use of medications: a growing concern.
    Vayda E
    Can Med Assoc J; 1976 Feb; 114(4):287-8. PubMed ID: 1253058
    [No Abstract]   [Full Text] [Related]  

  • 60. An old cancer drug's degrading new look.
    Kiberstis PA
    Science; 2017 Apr; 356(6336):392-394. PubMed ID: 28450621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.